arGEN-X raised a round of funding on September 27, 2010. Investors include
VLAIO.
arGEN-X (EBR: ARGX) (NASDAQ: ARGX) is a clinical stage human therapeutic antibody company that is rapidly developing a product pipeline using its unique suite of antibody technologies. arGEN-X is crea…
